TY  - JOUR
AU  - Pascual, Tomás
AU  - Oliveira, Mafalda
AU  - Ciruelos, Eva
AU  - Bellet Ezquerra, Meritxell
AU  - Saura, Cristina
AU  - Gavilá, Joaquin
AU  - Pernas, Sonia
AU  - Muñoz, Montserrat
AU  - Vidal, Maria J
AU  - Margelí Vila, Mireia
AU  - Cejalvo, Juan M
AU  - González-Farré, Blanca
AU  - Espinosa-Bravo, Martin
AU  - Cruz, Josefina
AU  - Salvador-Bofill, Francisco Javier
AU  - Guerra, Juan Antonio
AU  - Luna Barrera, Ana María
AU  - Arumi de Dios, Miriam
AU  - Esker, Stephen
AU  - Fan, Pang-Dian
AU  - Martínez-Sáez, Olga
AU  - Villacampa, Guillermo
AU  - Paré, Laia
AU  - Ferrero-Cafiero, Juan M
AU  - Villagrasa, Patricia
AU  - Prat, Aleix
PY  - 2021
DO  - 10.3389/fonc.2021.638482
SN  - 2234-943X
UR  - https://hdl.handle.net/10668/27194
T2  - Frontiers in oncology
AB  - Background: Preclinical data support a key role for the human epidermal growth factor receptor 3 (HER3) pathway in hormone receptor (HR)-positive breast cancer. Recently, new HER3 directed antibody drug conjugates have shown activity in breast cancer....
LA  - en
KW  - Breast Cancer
KW  - CelTIL Score
KW  - ERBB3
KW  - HER3
KW  - HER3-DXd
KW  - U3-1402
KW  - patritumab deruxtecan
TI  - SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer.
TY  - research article
VL  - 11
ER  -